New study combines app support and antibiotic after sex to fight HIV and STIs in youth
NCT ID NCT07510048
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests a mobile health program called PrEP Choice to help young people ages 13-24 start and stick with HIV prevention pills or shots. It also looks at whether taking the antibiotic doxycycline after sex (DoxyPEP) can prevent other sexually transmitted infections. About 200 participants who are at higher risk for HIV will be followed for up to 18 months to see if these tools work and are easy to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
13 to 24 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Age 13-24 years, inclusive; * Self-reports being at increased likelihood for HIV acquisition, defined as having anal sex with a male in their lifetime; * Owns an iOS or Android Smartphone and able to access all elements of the PrEP Choice package; * Not currently on PrEP and interested in learning more about PrEP; * Is not living with HIV; * Weighs at least 35 kg; * Willing to receive PrEP care from a provider at a participating ATN SC; * Able to understand, read, and speak English; * Able to participate at the study site; and * Willing and able to provide written informed consent. * If of legal age or otherwise able to provide independent informed consent as determined by local law and consistent with IRB policies: Willing and able to provide written informed consent for study participation. * If not of legal age or otherwise not able to provide independent informed consent as determined by local law and consistent with IRB policies: Parent or legal guardian is willing and able to provide written informed consent for study participation and potential participant is willing and able to provide written assent for study participation. Exclusion Criteria: * Female; * In a mutually monogamous sexual relationship with a partner not living with HIV for the past 12 months; * Currently participating in an interventional trial of PrEP agents, or prior enrollment in HPTN 083, HPTN 083-01, or any other study of long-acting PrEP (including PURPOSE- 2 lenacapavir study); * Plan to move within 18 months to an area inaccessible to a participating ATN SC; * An employee of the participating SC; or * Any concurrent participation in other clinical trials or behavioral intervention studies without prior approval from the protocol team. * Any other medical, behavioral, or other conditions that in the opinion of the SC Project Lead could interfere with adherence to study procedures or the individual's ability to remain in the study for an 18-month period or compromise interpretation of study results.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
San Francisco Department of Public Health
San Francisco, California, 94102, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38015, United States
-
Tulane University
New Orleans, Louisiana, 70112, United States
-
University Illinois Chicago
Chicago, Illinois, 60612, United States
-
University of South Florida
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pharmacist chat group help stop HIV?
- Can 'Queen Mothers' bring HIV testing to the doorstep?
- Scientists map HIV's hiding spots in early infection
- Can local clinics keep more people with HIV in care?
- Can a phone call keep HIV-Positive mothers and babies on track?
- Can a phone app and a health worker ease depression in rural HIV care?